
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is a promising biotechnology company with a strong focus on precision medicine in the field of oncology. Their extensive capabilities in identifying and validating translational biomarkers, along with a pipeline of clinical and preclinical product candidates targeting key drivers of disease, make them well-positioned for success in the competitive market of targeted therapeutics. With positive clinical trial results and a potential for off-label use in HLA-A*02:01-positive patients, IDEAYA Biosciences has a strong outlook for future revenue growth. However, as with any biotech company, there are risks involved, such as R&D and regulatory setbacks, potential competition, and commercial challenges. Despite these risks, we believe that the company's solid foundation and potential for success make it a promising investment opportunity.
Bears say
IDEAYA Biosciences is a developmental-stage biotech company working to develop targeted therapies for select cancer patient populations. While the company's clinical stage product candidates show promise, with plans to submit multiple regulatory packages and interim analysis of OS data in the middle of 2027, the current market domination of competitors in the mUM space and risks associated with developmental pipelines lead to a negative outlook on their stock.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares